Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07178730 |
| Title | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer (ADAPT-TN-IV) |
| Acronym | ADAPT-TN-IV |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | West German Study Group |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DEU |